Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) is now available.
Shanghai Pharmaceuticals Holding Co., Ltd. announced its unaudited interim results for the six months ending June 30, 2025. The results, prepared according to Chinese Accounting Standards, have been reviewed by the Board and Audit Committee. The company reported no significant risks affecting its operations during this period, and all directors confirmed the accuracy and completeness of the report.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and services, catering to a wide market in China and potentially beyond.
Average Trading Volume: 6,052,345
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$70.45B
Learn more about 2607 stock on TipRanks’ Stock Analysis page.